About Us
Cyprotex specialises in preclinical ADME Tox, both in vitro (laboratory experiments) and in silico (computer modelling). Cyprotex was founded in 1999, and in 2002 it was listed on the London Stock Exchange’s AIM Market (symbol CRX, information for investors). Our headquarters are in Macclesfield, UK, near Manchester.
Cyprotex services all types and sizes of drug-discovery organisations, from the largest pharmaceutical companies to the smallest virtual companies, as well as academic and not-for-profit laboratories. We also support the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Over 600 organisations trust Cyprotex for their ADME Tox research needs.
In 2010 Cyprotex acquired Apredica, a US-based pioneer in predictive toxicology and customised ADME research.
More about Cyprotex:
Our services:
- High Throughput ADME screening
- Customised ADME assays
- Genomic ADME assays
- In silico pharmacokinetic predictive modelling
- In vitro toxicology
- Integrated drug discovery services
Our Partners
Cyprotex closely collaborates with partner companies to provide our customers specialty assays and coordinated services. Our partners include:
Sygnature Discovery – for Integrated Drug Discovery
Contact Us
- Researchers: Contact us to learn more about how Cyprotex can improve the speed and efficiency of your pharmaceutical, agrochemical or consumer chemical research.
- Investors: Contact investor relations.
- Job Seekers: View our open positions.
- All Others: Department directory.
Genomic ADME - gADME™
Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME
In vitro Micronucleus Test
Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service
Drug Transporters
Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters
By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011
